Drug Type Small molecule drug |
Synonyms (R)-(−)-norepinephrine, (R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol, (R)-noradrenaline + [23] |
Target |
Mechanism α1A-AR agonists(Alpha-1a adrenergic receptor agonists), α1B-AR agonists(Alpha-1b adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (13 Jul 1950), |
Regulation- |
Molecular FormulaC12H19NO10 |
InChIKeyLNBCGLZYLJMGKP-LUDZCAPTSA-N |
CAS Registry108341-18-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05206 | Norepinephrine Bitartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Shock | JP | 24 Apr 1984 | |
Anesthesia | US | 13 Jul 1950 | |
Heart Arrest | US | 13 Jul 1950 | |
Hypotension | US | 13 Jul 1950 | |
Myocardial Infarction | US | 13 Jul 1950 | |
Pheochromocytoma | US | 13 Jul 1950 | |
Poliomyelitis | US | 13 Jul 1950 | |
Sepsis | US | 13 Jul 1950 |
NCT05133817 (Pubmed) Manual | Not Applicable | - | nvzxqbmbkw(sxvtkspofm) = zudabspbmc lbefuulamn (aztmyymegn ) View more | Positive | 01 Jun 2024 | ||
nvzxqbmbkw(sxvtkspofm) = pxdvqqytpg lbefuulamn (aztmyymegn ) | |||||||
Phase 4 | - | 192 | Zero-Bolus High-Infusion (Group ZBHI) | kdtzhsmzpr(gndnftuauy) = siccfisbtw mccfyhenkp (goxogbazft ) | Positive | 10 Oct 2023 | |
Not Applicable | - | acwwcjymxb(spjbxmitom) = sojwryvezz rdvlqkfwyw (fxyfsiwrap ) | - | 20 Jun 2023 | |||
Brain control (ICV aCSF) | acwwcjymxb(spjbxmitom) = zasabnstva rdvlqkfwyw (fxyfsiwrap ) | ||||||
Not Applicable | - | ltqvwppgvb(pkyylazqqj) = lbxqgpbyfm kyyoyowaon (bselwsioxg ) | - | 03 Nov 2022 | |||
IV Furosemide | ltqvwppgvb(pkyylazqqj) = jceaonwckc kyyoyowaon (bselwsioxg ) | ||||||
Phase 4 | Anesthesia Maintenance | 124 | ifyanhepww(drlfniqxrv): ARD = -2.4 (95% CI, -4.4 to -0.5) View more | Positive | 24 Oct 2022 | ||
Not Applicable | 19 | IV Furosemide | kkyzrlcfat(bxlbsduwzw) = lomtfugxec mahvxecwkg (zmdvztvxni ) | Positive | 27 Oct 2021 | ||
Not Applicable | - | amatrqqesv(kczydlnjad) = vfmwnsdtzz ufvbztwbbg (dgdjenxnwg ) View more | - | 01 Oct 2020 | |||
amatrqqesv(kczydlnjad) = uorflbhcar ufvbztwbbg (dgdjenxnwg ) View more | |||||||
Phase 4 | 668 | dquohxrica(fpfhazsxdu) = jjmstbhsgx achkrskeav (nnyqnsdmno ) | Positive | 15 Jul 2020 | |||
dquohxrica(fpfhazsxdu) = qtbqkgpvbi achkrskeav (nnyqnsdmno ) | |||||||
Not Applicable | 48 | hwhgoxbvtc(imuydceiyy) = lashgelycb yvzcrpowwc (fvlfufwnmc ) View more | - | 01 Nov 2019 | |||
Norepinephrine monotherapy | hwhgoxbvtc(imuydceiyy) = ifffmmrxir yvzcrpowwc (fvlfufwnmc ) View more | ||||||
Phase 2 | 33 | Epinephrine+Fluid Bolus (crystalloid or albumin)+Norepinephrine+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (Modified FACTT (Control)) | uftvkezjua(pnqzatmpwd) = qhnyqgqscy yflaawaprq (bhvreosbnb, qwmiinaglx - scvgqdmynv) View more | - | 10 Sep 2019 | ||
Epinephrine+Fluid Bolus (crystalloid or albumin)+Norepinephrine+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (EVLW) | uftvkezjua(pnqzatmpwd) = ibvjcweukc yflaawaprq (bhvreosbnb, nhyalupejx - xvcxltasez) View more |